Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
- PMID: 21935914
- PMCID: PMC3578343
- DOI: 10.1002/cncr.26553
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Abstract
Background: Prognosis after surgery for pancreatic ductal adenocarcinoma (PDAC) is typically reported from the date of surgery. Survival estimates, however, are dynamic and may change based on the time already survived. The authors sought to assess conditional survival among a large cohort of patients who underwent resection of PDAC.
Methods: Between 1970 and 2008, 1822 patients who underwent resection for PDAC with curative intent were identified. Kaplan-Meier and Cox regression analyses were performed to validate established predictors of survival, and results were compared with 2-year conditional survival.
Results: Actuarial survival was 18% at 5 years, with a median survival of 18 months. Multivariate analysis revealed that tumor size, lymph node ratio, and positive margins were associated with worse survival (all P < .001). Differences in actuarial versus conditional survival estimates were greater the more years already survived by the patient. The 2-year conditional survival at 3 years-the probability of surviving to postoperative year 5 given that the patient had already survived 3 years-was 66% versus a 5-year actuarial survival calculated from the time of surgery of 18%. Stratification of 2-year conditional survival by lymph node ratio and margin status revealed that patients with high lymph node ratio or positive margins saw the greatest increase in 2-year conditional survival as more time elapsed (both P ≤ .01).
Conclusions: Differences in actuarial versus conditional survival estimates were more pronounced based on the additional years already survived by the patient. Conditional survival may be a helpful tool in counseling patients with PDAC, as it is a more accurate assessment of future survival for those patients who have already survived a certain amount of time.
Copyright © 2011 American Cancer Society.
Figures
Similar articles
-
Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.JOP. 2012 Mar 10;13(2):199-204. JOP. 2012. PMID: 22406601
-
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.Cancer. 2010 Jul 15;116(14):3369-77. doi: 10.1002/cncr.25070. Cancer. 2010. PMID: 20564064 Free PMC article.
-
Conditional survival in pancreatic cancer: better than expected.HPB (Oxford). 2011 Dec;13(12):876-80. doi: 10.1111/j.1477-2574.2011.00379.x. Epub 2011 Sep 16. HPB (Oxford). 2011. PMID: 22081923 Free PMC article.
-
Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.Hepatobiliary Pancreat Dis Int. 2018 Oct;17(5):450-455. doi: 10.1016/j.hbpd.2018.09.003. Epub 2018 Sep 7. Hepatobiliary Pancreat Dis Int. 2018. PMID: 30237091
-
Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.HPB (Oxford). 2016 Jan;18(1):21-8. doi: 10.1016/j.hpb.2015.07.009. Epub 2015 Dec 21. HPB (Oxford). 2016. PMID: 26776847 Free PMC article. Review.
Cited by
-
Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study.Ann Surg Oncol. 2024 Feb;31(2):1178-1189. doi: 10.1245/s10434-023-14594-x. Epub 2023 Nov 30. Ann Surg Oncol. 2024. PMID: 38032467
-
Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses.Cell Rep Methods. 2023 Oct 23;3(10):100600. doi: 10.1016/j.crmeth.2023.100600. Epub 2023 Sep 29. Cell Rep Methods. 2023. PMID: 37776855 Free PMC article.
-
Conditional Risks of Biochemical Failure and Prostate Cancer-Specific Death in Patients Undergoing External Beam Radiotherapy: A Secondary Analysis of 2 Randomized Clinical Trials.JAMA Netw Open. 2023 Sep 5;6(9):e2335069. doi: 10.1001/jamanetworkopen.2023.35069. JAMA Netw Open. 2023. PMID: 37751207 Free PMC article.
-
Nomograms for Predicting the Risk and Prognosis of Liver Metastases in Pancreatic Cancer: A Population-Based Analysis.J Pers Med. 2023 Feb 24;13(3):409. doi: 10.3390/jpm13030409. J Pers Med. 2023. PMID: 36983591 Free PMC article.
-
Conditional Survival After Hepatectomy for Colorectal Liver Metastasis: Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC).Ann Surg Oncol. 2023 Jun;30(6):3413-3422. doi: 10.1245/s10434-023-13189-w. Epub 2023 Mar 1. Ann Surg Oncol. 2023. PMID: 36859704
References
-
- Jemal A, Siegel R, Xu J. Ward E. Cancer statistics. CA Cancer J Clin. 2010;2010;60:277–300. - PubMed
-
- Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210. - PubMed
-
- Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277. - PubMed
-
- Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
